August 28, 2026
Compelling new clinical evidence is adding rigour to the Dairy Goat Co-operative’s market-growth story as a leader in premium whole goat milk formula.
Co-funded by MPI and DGC, Caprine Innovations has supported international research into the whole goat milk formula DGC has pioneered for more than 30 years, alongside work to strengthen sustainable, resilient dairy goat farming in New Zealand.
A major milestone is publication of the GIraFFE study™ in Clinical Nutrition, a leading international medical journal. One of the largest multicentre, double-blind randomised controlled trials of its kind, involving more than 2,100 infants, GIraFFE tested DGC’s whole goat milk formula against standard cow milk formula.
It found whole goat milk formula significantly lowered the incidence of doctor-diagnosed atopic dermatitis (eczema) in formula-fed infants in their first year of life: a 34% reduction overall if the whole goat milk formula was continuously consumed, and a 64% reduction in infants with a family history of atopic dermatitis.
This matters because eczema affects around 10-30% of children worldwide, often appears in the first year of life, and is recognised as an early marker on the pathway towards other allergic conditions.
While being clear that breastfeeding is best, the findings add scientific rigour to DGC’s goal of making whole goat milk formula a preferred and genuine alternative to conventional formula made from cow milk. They also strengthen DGC’s premium global proposition, underpinned by goat milk’s natural protein profile and a whole goat milk recipe that sources around 50% of its fat from goat milk itself, preserving more of the natural characteristics of the milk.
That evidence base supports DGC’s renewed commercial momentum, including market growth, China re-entry planning and a sharper focus on milk supply resilience through its Formula for Success strategy.